▼ bearish
Impact
PhaseApproved / Commercialized
Time to marketAlready on the market (CE-marked in Europe, FDA-cleared in US)
CytoSorb hemoadsorption cartridge Updated Sep 5
What to watch
Watch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.
Bull case
- CEO Phillip Chan and CFO Peter Mariani collectively purchased ~$149K of stock in open-market transactions in June 2026 at ~$0.40-0.44/share, signaling management conviction at a micro-cap with bearish analyst consensus
- DrugSorb-ATR received FDA Breakthrough Device Designation (Nov 2025 and May 2026), which enables priority and interactive FDA review; a De Novo submission was made in Q1 2026
- Cash burn has been reduced to ~$200K/month (ex-restructuring), extending runway toward operating cash flow breakeven
Bear case
- Stock trades at ~$0.35, well below the $1.00 Nasdaq minimum bid price; must regain compliance by September 28, 2026 or face delisting, a reverse stock split would dilute and reduce liquidity
- Q2 2026 revenue was flat YoY at $9.6M with a GAAP net loss of $0.07/share, missing consensus EPS of -$0.04 by 75%
- Cash runway is limited at $5.9M, and the company is still loss-making